Dr.
Nathalie Bastard, PhD started her career as a Neuroscientist in academic
research, totaling 40+ peer-reviewed publications. She obtained a PhD in
Biomedical Sciences at the University of Antwerp, Belgium, in 2011, for her
work around the application of CSF biomarkers to aid in the differential
diagnosis of dementia. She was supported by a PhD fellowship from the
L’Oréal-UNESCO “For Women in Science”
program and the Fund for Scientific Research (FWO), and was awarded the
McKinsey and Company scientific prize.
She joined Fujirebio Europe (formerly known as
Innogenetics) in 2012 and currently holds the role of Strategic and Scientific
Affairs Manager. Nathalie’s experience is crucial for guiding the development
of clinical evidence for Fujirebio’s current biomarker portfolio and for
evaluating evidence to expand existing indications for use. She also
investigates new, innovative technologies and evaluates clinical utility and
applicability for novel biomarkers in diagnostic areas of interest. She is
responsible for developing the scientific publication strategy aimed to support
product development, market access and regulatory submissions globally. She is
an active and well-respected member of many local European and international
consortia and projects (e.g. GBSC, AD-RIDDLE,…).